Called orforglipron, the results of a new clinical trial announced Thursday by manufacturer Eli Lilly suggest that the pill could be a breakthrough in a class of drugs called GLP-1 agonists ...

But drug manufacturers and researchers recognize the perks of pills. An oral version of these drugs—which are known as glucagon-like peptide 1 (GLP-1) receptor agonists—could be more ...

A daily pill from drugmaker Eli Lilly has shown similar effectiveness at helping people reduce blood sugar levels and lose weight compared to leading injectable GLP-1 drugs Mounjaro and Ozempic ...

Now, a GLP-1 in pill form is showing promising results for weight loss and blood sugar control — no needles required. The medication — orforglipron from pharmaceutical giant Eli Lilly — is ...

Drugmaker Eli Lilly said Thursday that an experimental pill form of popular GLP-1 medications helped people with type 2 diabetes lose an average of nearly 8% of their body weight after 40 weeks ...

New research released Thursday morning shows a new, oral GLP-1 pill may be just as beneficial to those with Type 2 diabetes as injectable GLP-1 drugs. Drugmaker Eli Lilly said that in Phase 3 ...

Orforglibron, a pill form of GLP-1 weight loss injections like Ozempic and Mounjaro, is undergoing clinical trials. Drugmaker Eli Lilly said the first trial showed similar weight loss and diabetes ...

Just days after Pfizer pulled its experimental obesity pill, Eli Lilly announced promising results for its oral GLP-1. The pharma giant announced Thursday morning that its oral GLP-1 drug advanced ...